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Abstract: Many diseases, including cancer, can lead to neuropathic pain (NP). NP is one of the accompanying symptoms of suffering in many conditions and the life quality of NP patient is seriously
affected. Due to complex causes, the effects of clinical treatments have been very unsatisfactory.
Many experts have found that neuron-microglia interaction plays an essential role in NP occurrence and development. Therefore, the activation of microglia, related inflammatory mediators and
molecular and cellular signaling pathways have become the focus of NP research. With the help
of modern functional imaging technology, advanced pre-and clinical studies have been carried out
and NP interventions have been attempted by using the different pharmaceuticals and the extracted
active components of various traditional herbal medicines. In this communication, we review the
mechanism of microglia on NP formation and treatment and molecular imaging technology’s role in
the clinical diagnosis and evaluation of NP therapies.
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1. Introduction
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In 1994, the International Association for the Study of Pain (IASP) defined NP as the
pain caused by primary injury or dysfunction of the nervous system [1]. In 2011, the IASP
redefined the definition to pain caused by injuries directly or diseases of the peripheral
or central somatosensory system. NP is a common chronic pain condition that originates
from direct or metabolic diseases and viral infections. Traumatic injury or chemotherapyinduced peripheral or central nervous system (CNS) injury can lead to this disorder, which
influences the signal transduction mechanism of nerves in the dorsal root ganglion (DRG),
spinal cord and brain tissue. NP patients mainly manifest with physical symptoms such
as dysesthesias, paresthesia, spontaneous pain, allodynia, hyperalgesia and other various
features [2]. A common type of NP caused by cancer is malignant neuropathic pain (MNP).
This disease produces severe adverse consequences for these patients’ quality of life.
In the CNS, glial cells account for about 70% of the total number of cells. Glial cells
include oligodendrocytes, astrocytes, ependymal cells, Schwann cells, microglia and satellite cells. Microglia account for 5~20% of total glial cells [3]. The microglia, the resident
macrophages, are not dormant cells in a resting state. They can detect environmental
changes and cooperate with other cells/neurons to maintain homeostasis. Microglia
respond quickly with morphological changes when stimuli affect the physiological homeostasis of the CNS: microglia numbers increase, volume increases, processes retract and
become ramified. Activated microglia have two polarization types: M1-type (M1) and
M2-type (M2), pro-inflammatory and anti-inflammatory, respectively. M1 microglia have
a strong phagocytic ability and can produce many pro-inflammatory factors [4,5]. It is
known that NP is related to a change in the proportion of microglia polarization types,
M1/M2. As microglia are the critical cells in the pathogenesis of NP, selective inhibition
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of M1 or promotion of M2 microglia polarization has long been a subject for research and
target for treatment of NP.
NP is a complex problem in clinical pain treatment and NP incidence is very high [6,7].
The etiology and mechanisms of NP are more complex than traumatic pain. Cancers
can easily induce nerve injury that leads to NP due to the compression of the nerve
tissue, the toxic reaction from radiotherapies and chemotherapies, surgery and other
symptomatic factors.
In recent efforts to advance the treatments of NP, experts have tried to control the
pain by inhibiting activated microglia. Furthermore, in recent years, renewed attention
has been paid to glial cells’ role in NP and in particular their role in the CNS [8]. In this
communication, the effect of microglia on NP and the related interventions and specific
imaging approaches are reviewed.
2. Mechanisms Related to Microglia Activation
After stimulation from harmful factors, microglia respond quickly and are activated.
Activated microglia can induce and release nociceptive inflammatory mediators. The
main targets of current pain research include chemokines (CC), interleukins (IL), colonystimulating factors (CSF), tumor necrosis factors (TNF), the inducible isoform of nitric
oxide synthase (iNOS) and cyclooxygenase 2 (COX-2). Furthermore, microglia can directly
express specific neurotransmitter receptors related to pain, such as G protein-coupled
receptors and ionotropic receptors. Receptor expression activates intracellular signal
pathways and enables microglia to respond to changes in their microenvironment quickly
and effectively.
2.1. Major Inflammatory Mediators
2.1.1. Chemokines (CCs)
Chemokines are critical inflammatory mediators between peripheral sensory neurons
and glial cells. Chemokines function to regulate the migration and activation of white
blood cells. These factors regulate the production and development of NP and are related to
various CC receptor subtypes found in the CNS. CC ligand 2 (CCL2) binds to CC receptor
2 (CCR2) with the highest affinity [9,10], a receptor expressed on the microglia found in
the spinal cord. CCR2 interact with other chemokines such as CCL7, CCL8 and CCL13.
Some studies have shown that intraspinal injection of CCL2 induced extensive microglia
activation in the ipsilateral spinal dorsal horn. CCR2 antagonists have been demonstrated
to increase animal pain threshold effectively, which suggests that the binding of CCL2 and
CCR2 is involved in the interaction between neurons and microglia and the maintenance
of hypersensitization in NP [11,12].
C-X3-C motif chemokine ligand 1 (CX3CL1) mainly exists in CNS neurons, peripheral
DRG neurons and primary afferent neuron endings. CX3CL1 receptors are primarily expressed in the microglia of the brain and spinal cord. CX3CL1 becomes soluble upon the
action of protease cathepsin S (Cat S) secreted by microglia. When peripheral nerve injury
occurs, microglia increase Cat S secretion. One finding showed that if a Cat S inhibitor was
given to rats, CX3CL1 would return to a normal level and touch-induced pain would be inhibited [13]. CCL21 mainly exists in unmyelinated sensory neurons and can be transported
to the terminals of primary afferent neurons through spinal dorsal root axons. Normal DRG
neurons scarcely express CCL21, but peripheral nerve injury can trigger CCL21 expression.
Mice deficient of CCL21 expression did not develop NP post spinal nerve injury, while
supplemental CCL21 administration activated spinal microglia and induced persistent
pain [14]. The specific antibody of CCL21 can significantly inhibit the aforementioned
symptoms, suggesting that CCL21 plays a particular role in microglial activation and
NP [10]. However, the mechanisms by which CCL21 acts directly or indirectly on microglia
remain to be investigated.
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2.1.2. Tumor Necrosis Factor-α (TNF-α)
TNF-α is the most crucial pro-inflammatory factor in nerve injury and the inflammatory response. TNF-α expression remained low or none in normal conditions. However,
after peripheral nerve injury, TNF-α promotes Na+ influx and decreased excitatory threshold by activating the p38-MAPK pathway in DRG neurons. In the spinal cord, TNF-α is
involved in the regulation of the NP through glutamate receptors (NMDA, AMPA, etc.)
and the regulation of glutamate receptors may be a potentially effective target for NP
therapy [15]. The expression of TNF-α and NF- kappa β are directly or indirectly related.
In the DRG and the spinal dorsal horn, TNF-α can activate NF- kappa B by binding to its
receptor. After that, the expression of other pro-inflammatory factors is induced, causing a
cascade reaction that leads to the production of pain. In addition, the expression of TNF-α
can lead to the upregulation of its primary receptor TNFR1 [16,17], which inhibits the
spontaneous action potential of GABA neurons and weakening the inhibitory regulation of
GABA [18], thus producing the pain effect found in NP.
2.1.3. Interleukin-1β (IL-1β)
IL-1β is another cytokine that plays a vital role in the regulation of NP. The production
of IL-1β is closely related to the activation of glial cells. Stimulated by pathological pain,
microglia in the spinal dorsal horn are rapidly activated and change in morphology and
function. These changes result in the up-regulation of IL-1β, NMDAR and phosphorylation
of NMDA receptors (NR1 and NR2B) [19], changes in these expressions enhance pain
conduction and promote the formation of pain sensitivity [20]. Intrathecal injection of the
IL-1β specific antibody can prevent pain allergic reaction induced by MMP-9, indicating
that IL-1β is involved in the development of NP [21].
2.1.4. Colony Stimulating Factors (CSFs)
CSFs are cytokines involved in the proliferation and differentiation of hematopoietic
stem cells into specific leukocytes such as macrophages and granulocytes. M-CSF is mainly
expressed in DRG neurons and its receptor is only expressed in microglia of the spinal cord.
It has been found that M-CSF can act on M-CSF receptors to promote the activation and
proliferation of microglia through the immunomodulatory adapter protein DAP12 located
on the microglia membrane. Thus, due to the role of M-CSF in the regulation of NP, mice
lacking the M-CSF gene could prevent the activation of microglia and the occurrence of NP
after peripheral nerve injury [22,23].
2.1.5. Inducible Nitric Oxide Synthase (iNOS)
iNOS is an essential rate-limiting enzyme for nitric oxide synthesis. Excessive levels
of iNOS are known to activate microglia. Activated microglia in the spinal cord could
produce reactive oxygen species, nitric oxide, and inflammatory mediators - all of which
are involved in pain hypersensitivity. Thus, peripheral nerve injury could lead to the overexpression of iNOS in the spinal cord. Results have suggested that systemic or intrathecal
injections of an iNOS inhibitor could have effective analgesic properties for NP in WT
mice. In contrast, iNOS knockout KO mice did not show hyperalgesia or abnormal pain
symptoms induced by nerve injury [24].
2.1.6. Cyclooxygenase-2 (COX-2)
COX-2 is mainly expressed in the cell body, proximal dendritic process and distal
dendritic spine in neurons of the CNS. In the peripheral nervous system, COX-2 is highly
expressed in macrophages and Schwann cells. In the resting state, microglia only express a
small amount of COX-2. However, under the stimulation of inflammatory substances such
as lipopolysaccharides (LPS), the morphology of microglia changes and the COX-2 mRNA
and protein expression increase rapidly. At the same time, these changes promote the
release of neurotoxic substances: TNF-α, IL-1, IL-6 and NO which are known to damage
neurons and consequently lead to NP [25].
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pathway had a negative regulatory mechanism. PTEN is a tumor inhibitor gene, which
could inhibit the PI3K/AKT signaling pathway [31].
2.2.3. MAPK Signaling Pathway
Three signaling pathways, p38 mitogen-activated protein kinase (p38MAPK), extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), are mainly
involved in the regulation of NP. P38MAPK is the crucial intracellular signaling molecule
that regulates the pain signals of microglia. The phosphorylation of p38MAPK occurs
in microglia. The expression of TLRs, P2X4R, P2X7R, P2Y12/13R and other membrane
receptors is upregulated after the activation of spinal cord microglia [32]. The phosphorylation of p38 MAPK can increase the expression and synthesis of inflammatory factors
and chemokines, promote the formation of central hyperalgesia of pain and facilitate pain
signal transduction [33]. It has been proved that intrathecal injection of p38MAPK inhibitor
SB230580 into an animal model of neuronal pain can reduce the pain sensation [34]. Still,
a p38MAPK inhibitor can only prevent the occurrence and development of chronic NP,
not reverse the pain symptoms. The mechanism of SB230580 is still unclear. ERK is an
extracellular signal-regulation protease of the MAPKs family. ERK1/2 phosphorylation
is closely related to NP pain-sensitive changes and appears in microglia a few days after
nerve injury. Increased ERK1/2 phosphorylation is accompanied by up-regulation of
inflammatory factors IL-1 β and IL-6 as well as TNF-α at the mRNA level. Inhibition of
ERK can relieve mechanically tactile induced pain and weaken the central sensitization of
the spinal dorsal horn [35–37]. JNK is known as s stress-activated protein kinase (SAPK). It
has been suggested that the JNK signaling pathway is mainly involved in the maintenance
of NP [38]. MAPK (ERK1/2 and JNK) may act as upstream signaling molecules for NF-κB
activation. If the JNK pathway is suppressed, then NF-κB expression could be decreased,
leading to the down-regulation of IL-6 and TNF-α at the transcription and translation
levels, respectively [39].
2.2.4. TLR4/NF-κB Signaling Pathway
NF-κB is a nuclear transcription factor in B lymphocytes that are involved in the
regulation of many cytokines. In the nervous system, NF-κB only exists in two subtypes
of p50 and p65. NF-κB mainly regulates the inflammatory response through classical and
non-classical pathways. Cytokine receptors and toll-like receptors (TLR) are involved in
the classical pathways. TLRs are pattern recognition receptors primarily expressed in glial
cells in the rodent CNS. In a NP animal model of nerve injury, mechanical hyperalgesia
and thermal hyperalgesia are closely associated with TLR4 overexpression in the spinal
cord microglia. [40,41]. Inhibiting the expression of TLR4 could reduce the activation of
microglia, the release of inflammatory mediators and lessen the hyperalgesia. TLR4/NFkappa B is a non-Ca2+ dependent pathway of pain signal transduction. When peripheral
nerve injury occurs, nociceptive transmitters combine with TLR4 and activate the receptor,
NF-κB, downstream related factors and microglia. This cascade promotes the synthesis and
release of IL-6, IL-1β, TNF-α, iNOS and COX-2 to sensitized spinal dorsal horn neurons,
which ultimately causes NP [42,43]. Thus, inhibition of the TLR4/NF- kappa B pathway
may be one of the most effective strategies for anti-inflammatory therapies of NP.
2.2.5. Notch Signaling Pathway
The Notch signaling pathway is comprised of Notch receptors, Notch ligands (DSL
protein), NICD transport molecules and downstream Hes/Hey [44]. The Notch signaling
pathway plays an essential role in the activation and proliferation of glial cells. LPS can
activate microglia in a resting state. Activated M1 microglia express a large number of
Notch1, Notch2 and ligand Jagged1. Downstream target genes Hes-1 and RBPJ kappa
release many inflammatory mediators that significantly decrease pain threshold, such as
IL-6, TNF-α, IL-1β and iNOS [45,46]. After blocking the Notch signaling pathway with
DAPT, M1 cells reduce inflammatory mediators and evolved into M2 cells. Inhibition of the
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Notch signaling pathway can significantly impede microglia activation, thus, decreasing
the expression of pro-inflammatory cytokines and in turn reduce the injury to neurons
and reverse the hyperalgesia. In addition, NF-κB, as the downstream factor of the Notch
signaling pathway, also plays an essential role in regulating the expression of IL-1β, IL6, TNF-α, iNOS and other inflammatory mediators [47]. Whether the Notch signaling
pathway could activate microglia directly or indirectly and whether it interacts with
different pathways remains to be confirmed by further studies.
3. Intervention Studies Related to Microglia
Focusing on the mechanism of microglia activation and NP, the purpose of this
study was to reverse NP by discovering microglia inhibitors or blocking related signaling
pathways. At present, the research on drug therapies for NP is mainly focused on the
mechanism and clinical efficacy of the combined use of third-line drugs and drug and nondrug cocktails. The scope of current research aims to increase the therapeutic effectiveness
and reduce adverse reactions to NP. Some research is carried out at the molecular level. As
an inhibitor of microglia activation, minocycline (MI) reduces the expression and release
of pain-causing substances such as IL-1, TNF-α and CX3CL1. MI directly acts on ion
channels and inhibits the phosphorylation of intracellular kinases such as MAPKs and thus
could effectively alleviate NP. Edaravone may inhibit the activation of the Notch signaling
pathway and the NF-kappa B signaling pathway, PI3K/Akt. The regulated expression of
NF-kappa B could decrease the release of related inflammatory mediators. Glial inhibitor
propento-fylline (PPF), a methylxanthine derivative, can inhibit the activation of glial cells,
antagonize the release of active substances and inhibit the release of inflammatory factors
nitric oxide and other related substances [48–50]. However, there is no definite report on
whether these chemicals have been used and how effective they may be. Studies in animal
models have explored the molecular signal pathways and related inflammatory mediators
of NP by utilizing biologically active molecules extracted from traditional herbal medicines
known to produce analgesic effects.
3.1. NF-Kappa B Signaling Pathway
Curcumin is the main biologically active component extracted from turmeric roots.
Curcumin could inhibit the activation of NF- kappa B and down-regulate the expression of
Toll-like receptor4 and spinal cord CX3CR1 by down-regulating the activities of nuclear
factor kappa-B kinase (Ik-Bk) and protein kinase B (Akt) inhibitors. Some studies have also
shown that curcumin could inhibit microglia activation and reduce the release of LDH,
TNF-α, IL-1β and IL-6 by inducing LPS through the JAK2 / STAT3 signaling pathway,
thereby controlling the formation of NP. Tetramethypyrazine (TMP) is an alkaloid isolated
from Ligusticum chuanxiong. Ligustrazin can increase the mechanical pain threshold and
the thermal claw latency in rats and has a pronounced analgesic effect. Resveratrol could
effectively relieve thermal pain and mechanical pain, especially in severe pain, by inhibiting
the activation of the NF-kappa B signaling pathway and decreasing the expression of NFkappa B and the release of many inflammatory cytokines such as TNF-α. Catalpol is
a small molecule compound of iridoid extracted from the root of Rehmannia glutinosa.
Studies have shown that catalpol could regulate TNF-α and Akt, inhibiting the NF- kappa
B signaling pathway, thus inhibiting the activation of microglia and reducing the release of
inflammatory factors [51–55].
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3.2. MAPK Signal Pathway
Tanshinone IIA, the main active component of Salvia miltiorrhiza, can effectively
inhibit the spinal cord microglia activation in the spinal nerve ligation (SNL) animal model.
The mechanism is related to the inhibition of MAPKs activation and the resulting decreased
expression of TNF-α and IL-1β. Polygonum cuspidatum extract has a significant inhibitory
effect on mechanical hyperalgesia induced by CCI and its mechanism may be related to
the inhibition of p38 phosphorylation in spinal cord microglia. Procyanidins (PC) is a
natural flavonoid existing richly in grape seeds, blueberries, cherries and other plants.
PC could improve opioid-induced hyperalgesia (OIH) by inhibiting microglia activation
and inhibiting the pd38MAPK pathway, reducing the response of LPS induced inflammation [56–58]. Tripterygium wilfordii could inhibit microglial activation, the phosphorylation
of MAPKs and the overexpression of inflammatory cytokines such as IL-6, IL-1β, TNF-α
and Monocyte Chemotactic Protein (MCP-1). Gastrodin could be effectively used in the
treatment of NP as it inhibits vincristine-induced hyperalgesia in rats. Its mechanism may
be related to the inhibition of ERK1/2 and the activation of spinal microglia [59–61].
3.3. Other Inflammatory Mediators
Corydalis, extracted from the tuber of the poppy family, is commonly used in traditional herbal medicine for relieving pain. Elaeagnus angustifolia contains a variety of
alkaloids among which, tetrahydropalmatine B has the most potent analgesic effect. It
has been shown to increase the pain threshold of chemotherapy pain rat models, which
may be related to its inhibition of the expression of TNF-α, IL- 1β and other inflammatory
cytokines in the lumbar segment of the spinal cord [62]. Iridoid glycosides could significantly
relieve mechanical tactile pain and temperature hyperalgesia via decreased NOS activity
and NO levels as well as inhibition of iNOS mRNA expression in the spinal cord [63]. Both
hookitin and artemisolactone were shown to reduce the production of inflammatory factors
TNF-α, IL-1β and IL-6 in microglia induced by LPS and effectively relieve NP hyperalgesia.
Cinobufagin could significantly relieve mechanical pain and thermal pain sensitivities in
rats by inhibiting the activation of rat spinal cord microglia and reducing the release of
TNF-α, IL-1β and other related inflammatory mediators by spinal cord glial cells.
The current systematic and comprehensive research of NP medicine is still preliminary.
Generally speaking, the experimental study of the active components in traditional herbal
medicine and the analgesic mechanisms of microglia is dispersed and insufficient. Thus,
questions remain to be answered, such as whether the active ingredients of traditional
herbal medicine can be directly applied to the clinical treatment of NP, whether the combination of different treatments for different NP targets has a synergistic effect and whether a
more effective procedure can be developed to minimize the side effects caused by existing
NP therapies.
4. Neuroimaging of Microglia Activation
Many imaging technologies had been used as new research methods such as noninvasive or less invasive positron emission tomography (PET), single-photon emission
computed tomography (SPECT), magnetic resonance imaging (MRI) and other neuroimaging techniques to study the relationship between the occurrence and developmental mechanisms and imaging of chronic pain, including NP. As a result, researchers can now observe
the activation process of glial cells dynamically and quantitatively in vivo and develop
new clinical diagnostic procedures and more effective evaluations of NP treatments [64].
4.1. Imaging via Targeting Opioid Receptor
Opioid receptors are the most central receptors to the study of pain and analgesia.
Quantitative detection of µ, σ and κ opioid receptors and their signal transduction in the
brain could provide direct insight into pain mechanisms. PET tracers such as [11 C]DPN,
[11 C]carfentanil and [11 C]Diprenorphineand and SEPCT tracers such as [123 I]DPN and
[123 I]-o-IA-DPN have been widely used in functional imaging techniques. These tracers
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could show regional differences in opioid receptor densities and subtype distributions,
providing methods for the dynamic study of opioid receptor distribution and changes
under physiological and pathological conditions [65].
In chronic pain, endogenous opioid peptides are released, vandalized and downregulated. Subsequently, the binding affinity of opioid receptors to radiotracers also decreases.
The motor cortex stimulation (MCS) for NP control studies showed that the binding of
[11 C]DPN in the frontal cortex, anterior middle cingulate cortex (aMCC) and periaqueductal gray (PAG) is significantly decreased. The binding changes in aMCC and PAG
substantially correlate with the degree of pain relief, indicating that MCS could induce
the release of endogenous opioid peptides from the brain to attenuate chronic pain [66].
However, because various factors regulate the opioid receptor activation and its binding
state to ligands, opioid receptor PET imaging alone may not fully reveal the complex nature
of this receptor and its changes throughout the NP developments and interventions.
4.2. Imaging via Targeting Translocator Protein
Translocator protein 18 kDa (TSPO), also known as peripheral benzodiazepine receptor
(PBR), is well characterized as a biomarker of neuropathological changes in vitro and
in vivo. The expression of TSPO in resting microglia is low, but it is upregulated in
activated microglia, suggesting that TSPO may be involved in microglia activation and
could serve as a biomarker for neuroinflammation. PET imaging studies using TSPO
radiotracers [11 C]PK11195 and [11 C]PBR28 have shown that the uptake of both tracers
is significantly higher in the patients suffering from pain compared to controls in the
thalamus, anterior and posterior central gyrus and the paracentral lobule. This finding
suggests that the activation of human microglia is pain-related, as is the secretion of
inflammatory mediators such as TNF-α, IL-1β, IL-6 and COX-2 [67,68]. After activation
of TSPO by endogenous or exogenous ligands, the transportation of TSPO-dependent
cholesterol to mitochondria is accelerated and neuro-steroid production is increased. Some
TSPO ligands, such as Ro5-4864, etifoxine, AC 5216 and MPIGA, have been shown to
mediate the increase of neuro-steroid hormone production. Ro5-4864 had neuroprotective
and anxiolytic effects and effectively attenuated the anxiety and other related symptoms
caused by nerve injury [69,70]. In a rat model of the development of NP, TSPO PETCT imaging of the lumbar spinal cord showed decent aggregation of [11 C]PK11195 in
conjunction with the glial cell increases in the spine [71]. These studies suggest that TSPO
PET might be valuable for evaluating the glia activation involved in NP.
4.2.1. PBR28 Binding Affinity
To measure the TSPO binding affinity of PBR28 and the TSPO receptor density in
the brain tissue, [3 H]PBR28 was synthesized by American Radiolabeled Chemicals, Inc.
(St. Louis, MO, USA). The specific activity of the radioligand was 80 Ci/mmol. Receptor
binding studies, both saturation and competitive assays were carried out with rat brain
tissue homogenates as reported [72,73]. The data showed that this radioligand has a very
high binding affinity with a dissociation constant Kd = 1.4 nM, high maximum receptor
binding sites Bmax = 355 fmol/mg protein and low nonspecific binding to TSPO in the rat
brain membrane homogenates. Known TSPO selective small-molecule ligands, FEPPA,
PK11195 and PBR28, displaced the binding sites with high affinity, expressed as dissociation
constants Ki of 0.32 nM, 0.88 nM and 2.2 nM, respectively (Figure 2A–C).
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4.3. [18F]FDG PET Imaging
Toadate,
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been developed
specifically
targetinmicroglia
and
In
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PET/MRI to
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locating hy11 C]CPPC [77]
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using
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colony-stimulating
factor
1
receptor
(CSF1R)
tracer
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[78,79].
more,
earlier
[18F]FDG binding
PET/CT sites
imaging
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NPrespectively
showed there
are
TSPO
probes,
together
with
these
novel
human
glia
PET
tracers,
will
benefit
the
NP
research
decent radioactivity uptakes in the nodular, fasciculate and root whisker along the nerve
community
by aiding
to dissect
the individual
roles ofor
glia
subtypes
in pain
sensation.
root
and bundles
in peripheral
nerves
with metastases
tumor
invasion;
suggesting
that
[18F]FDG PET/CT could measure the density, distribution and structure of nerves involved
[18 F]FDG
Imaging
in4.3.
patients
withPET
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NP pain. However, the influence of iatrogenic factors such
In a recent
clinical
investigation,
F]FDG PET/MRI
showed
promises
in locating
as puncture,
surgery,
radiotherapy
and[18
chemotherapy,
etc. on
the nerve
SUVmax
needs
abnormalities in the non-brain brain regions of NP patients [80]. Furthertohypermetabolic
be excluded [81,82].
more, earlier [18 F]FDG PET/CT imaging studies of carcinomatous NP showed there are
decent radioactivity uptakes in the nodular, fasciculate and root whisker along the nerve
root and bundles in peripheral nerves with metastases or tumor invasion; suggesting that
[18 F]FDG PET/CT could measure the density, distribution and structure of nerves involved
in patients with carcinomatous NP pain. However, the influence of iatrogenic factors such
as puncture, surgery, radiotherapy and chemotherapy, etc. on the nerve SUVmax needs to
be excluded [81,82].
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5. Conclusions and Prospect
The pathogenesis of NP is complex, but many studies have confirmed that microglia
activation is involved in the development of NP. The microglia activation, up-regulation
of specific membrane receptors, enhancement of the intracellular signaling pathways and
the release of pain-related inflammatory mediators are the pathophysiological basis for
the occurrence and development of NP. Although these studies are limited to cell and
animal experiments, these beneficial explorations have deepened our understanding of
NP. At present, drugs are still an essential means of NP treatment and antidepressants and
anticonvulsants are the first-line drugs for NP treatment and opioid analgesic drugs have
a synergistic effect. In addition, medications such as nerve blocks, electrical stimulation,
intrathecal analgesia pumps, nerve injury and other non-drug therapies also play essential
roles in alleviating NP. In addition, psychological and behavioral interventions play a
positive role in auxiliary treatments. However, outstanding problems remain, such as
the difficulties in reversing pain sensitivity, significant individual differences in curative
effect, drug tolerance, noticeable side effects, etc. As the symptomatic effects of NP are not
ideal, these are still complex and thorny problems in global pain treatment. The modern
molecular imaging technology via targeting TSPO using PBR28 or other specific biomarkers
of microglia and astrocytes activation will advance the clinical diagnosis and evaluation
of the NP pharmaceutics. Furthermore, more potent radiotracers specifically targeting
microglia or astrocytes will be needed for further understanding the cellular mechanisms
of glia activation in NP and accelerate the finding of effective interventions that target
glia activation.
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